These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30001521)

  • 1. Immune Correlate-Guided HIV Vaccine Design.
    Alter G; Barouch D
    Cell Host Microbe; 2018 Jul; 24(1):25-33. PubMed ID: 30001521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
    Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV/AIDS: vaccines and alternate strategies for treatment and prevention.
    Voronin Y; Phogat S
    Ann N Y Acad Sci; 2010 Sep; 1205 Suppl 1():E1-9. PubMed ID: 20860672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
    Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B
    Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.
    Ringel O; Vieillard V; Debré P; Eichler J; Büning H; Dietrich U
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29662026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting.
    King HAD; Gonelli CA; Tullett KM; Lahoud MH; Purcell DFJ; Drummer HE; Poumbourios P; Center RJ
    PLoS One; 2019; 14(8):e0220986. PubMed ID: 31430333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding.
    Kulp DW; Steichen JM; Pauthner M; Hu X; Schiffner T; Liguori A; Cottrell CA; Havenar-Daughton C; Ozorowski G; Georgeson E; Kalyuzhniy O; Willis JR; Kubitz M; Adachi Y; Reiss SM; Shin M; de Val N; Ward AB; Crotty S; Burton DR; Schief WR
    Nat Commun; 2017 Nov; 8(1):1655. PubMed ID: 29162799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
    Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
    J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of Ebola glycoprotein into HIV particles facilitates dendritic cell and macrophage targeting and enhances HIV-specific immune responses.
    Ao Z; Wang L; Mendoza EJ; Cheng K; Zhu W; Cohen EA; Fowke K; Qiu X; Kobinger G; Yao X
    PLoS One; 2019; 14(5):e0216949. PubMed ID: 31100082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RV144: old vs. new.
    Weiner DB
    Hum Vaccin; 2010 Feb; 6(2):159-61. PubMed ID: 20431335
    [No Abstract]   [Full Text] [Related]  

  • 13. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus.
    Schell JB; Bahl K; Folta-Stogniew E; Rose N; Buonocore L; Marx PA; Gambhira R; Rose JK
    Virology; 2015 Feb; 476():405-412. PubMed ID: 25591175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is an HIV vaccine possible?
    Wilson NA; Watkins DI
    Braz J Infect Dis; 2009 Aug; 13(4):304-10. PubMed ID: 20231996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moving the HIV vaccine field forward: concepts of protective immunity.
    Kent SJ; Davenport MP
    Lancet HIV; 2019 Jun; 6(6):e406-e410. PubMed ID: 31080107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
    Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).
    Killick MA; Grant ML; Cerutti NM; Capovilla A; Papathanasopoulos MA
    Vaccine; 2015 Nov; 33(46):6298-306. PubMed ID: 26432912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward an antibody-based HIV-1 vaccine.
    Hoxie JA
    Annu Rev Med; 2010; 61():135-52. PubMed ID: 19824826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.